M Lizeth Orozco Morales

Years Active: 2023-2023
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

M Lizeth Orozco Morales, Catherine A Rinaldi, Emma de Jong, Sally M Lansley, Y C Gary Lee, Rachael M Zemek, Anthony Bosco, Richard A Lake, W Joost Lesterhuis
Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma. PloS one 18 (5) (2023)
M Lizeth Orozco Morales, Catherine A Rinaldi, Emma de Jong, Sally M Lansley, Y C Gary Lee, Rachael M Zemek, Anthony Bosco, Richard A Lake, W Joost Lesterhuis
Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma. PloS one 18 (5) (2023)
M Lizeth Orozco Morales, Catherine A Rinaldi, Emma de Jong, Sally M Lansley, Y C Gary Lee, Rachael M Zemek, Anthony Bosco, Richard A Lake, W Joost Lesterhuis
Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma. PloS one 18 (5) (2023)
M Lizeth Orozco Morales, Catherine A Rinaldi, Emma de Jong, Sally M Lansley, Y C Gary Lee, Rachael M Zemek, Anthony Bosco, Richard A Lake, W Joost Lesterhuis
Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma. PloS one 18 (5) (2023)

M Lizeth Orozco Morales.css-eqlu8i{font-size:small;padding-left:4px;}